UK Approves Bayer’s Xarelto for Venous Thromboembolism

February 4, 2021

UK regulators have approved Bayer’s Xarelto (rivaroxaban) to treat venous thromboembolism (VTE) and to prevent VTE recurrence in children from infancy to 18 years, following five days of initial intravenous anticoagulation treatment.

The drug is the first oral Factor Xa inhibitor, a type of anticoagulant approved for both pediatric use and secondary prevention of VTE.

The authorization from the UK’s Medicines and Healthcare products Regulatory Agency followed a positive recommendation last year from the European Medicines Agency.

View today's stories